EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Andrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, Thomas Bieber, Esther Serra-Baldrich, Eric Simpson, David Rosmarin, Hany Elmaraghy, Eric Meskimen, Chitra R Natalie, Zhuqing Liu, Chenjia Xu und 4 weitere

British Journal of Dermatology · 24.05.2023 · 188 (6) · 740-748

DOI: 10.1093/bjd/ljad022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 30.03.2023. Verfasst von Andrew Blauvelt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Medical Research Center, Portland, OR, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dermira, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13.

Objectives

To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).

Methods

Patients who responded to lebrikizumab 250 mg every 2 weeks (Q2W) at the end of the 16-week induction period were re-randomized 2 : 2 : 1 to receive lebrikizumab Q2W, lebrikizumab 250 mg every 4 weeks (Q4W) or placebo Q2W (lebrikizumab withdrawal) for 36 additional weeks. Response at week 16 was defined as achieving a 75% reduction in Eczema Area Severity Index (EASI 75) or an Investigator’s Global Assessment (IGA) of 0 or 1, with a ≥ 2-point improvement and no rescue medication use. Multiple imputation was used to handle missing data. Intermittent use of topical therapy was permitted during the maintenance period.

Results

After 52 weeks, an IGA of 0 or 1 with a ≥ 2 point improvement was maintained by 71.2% of patients treated with lebrikizumab Q2W, 76.9% of patients treated with lebrikizumab Q4W and 47.9% of patients in the lebrikizumab withdrawal arm. EASI 75 was maintained by 78.4% of patients treated with lebrikizumab Q2W, 81.7% of patients treated with lebrikizumab Q4W and 66.4% of patients in the lebrikizumab withdrawal arm at week 52. Across treatment arms, proportions of patients using any rescue therapy were 14.0% (ADvocate1) and 16.4% (ADvocate2). During the combined induction and maintenance periods of ADvocate1 and ADvocate2, 63.0% of lebrikizumab-treated patients reported any treatment emergent adverse event, with most events (93.1%) being mild or moderate in severity.

Conclusions

After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultAdolescentHumansAntibodies, Monoclonal, HumanizedTreatment OutcomeInjections, SubcutaneousDouble-Blind MethodSeverity of Illness IndexAntibodies, MonoclonalInterleukin-13Immunoglobulin A

Substanzen

lebrikizumabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterleukin-13Immunoglobulin A

Autor:innen und Institutionen

  • Oregon Medical Research Center, Portland, OR, USA.
  • Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • University Hospital Bonn, Bonn, Germany.
  • Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
  • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

ORCID-Profile: Jonathan I Silverberg

Förderung

  • Dermira
  • Eli Lilly and Company

Zitieren

APA

Blauvelt, A., Thyssen, J. P., Guttman-Yassky, E., Bieber, T., Serra-Baldrich, E., Simpson, E., Rosmarin, D., Elmaraghy, H., Meskimen, E., Natalie, C. R., Liu, Z., Xu, C., Pierce, E., Morgan-Cox, M., Garcia Gil, E., & Silverberg, J. I. (2023). Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology, 188(6), 740-748. https://doi.org/10.1093/bjd/ljad022

Vancouver

Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology. 2023;188(6):740-748. doi:10.1093/bjd/ljad022

BibTeX
@article{Blauvelt2023,
  author = {Blauvelt, Andrew and Thyssen, Jacob P and Guttman-Yassky, Emma and Bieber, Thomas and Serra-Baldrich, Esther and Simpson, Eric and Rosmarin, David and Elmaraghy, Hany and Meskimen, Eric and Natalie, Chitra R and Liu, Zhuqing and Xu, Chenjia and Pierce, Evangeline and Morgan-Cox, MaryAnn and Garcia Gil, Esther and Silverberg, Jonathan I},
  title = {Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {188},
  number = {6},
  pages = {740--748},
  doi = {10.1093/bjd/ljad022}
}
Kostenlos starten →